CA2312021C - Utilisation des ketolides pour prevenir les complications thrombotiques arterielles liees a l'atherosclerose - Google Patents

Utilisation des ketolides pour prevenir les complications thrombotiques arterielles liees a l'atherosclerose Download PDF

Info

Publication number
CA2312021C
CA2312021C CA002312021A CA2312021A CA2312021C CA 2312021 C CA2312021 C CA 2312021C CA 002312021 A CA002312021 A CA 002312021A CA 2312021 A CA2312021 A CA 2312021A CA 2312021 C CA2312021 C CA 2312021C
Authority
CA
Canada
Prior art keywords
methyl
dideoxy
radical
ketolide
ketolides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002312021A
Other languages
English (en)
French (fr)
Other versions
CA2312021A1 (fr
Inventor
Francis Petit
Francoise Vacheron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of CA2312021A1 publication Critical patent/CA2312021A1/fr
Application granted granted Critical
Publication of CA2312021C publication Critical patent/CA2312021C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA002312021A 1997-11-17 1998-11-16 Utilisation des ketolides pour prevenir les complications thrombotiques arterielles liees a l'atherosclerose Expired - Fee Related CA2312021C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9714358A FR2771008B1 (fr) 1997-11-17 1997-11-17 Utilisation des ketolides pour la preparation de compositions pharmaceutiques destinees a prevenir les complications thrombotiques arterielles liees a l'atherosclerose
FR9714358 1997-11-17
PCT/FR1998/002436 WO1999025365A1 (fr) 1997-11-17 1998-11-16 Utilisation des ketolides pour prevenir les complications thrombotiques arterielles liees a l'atherosclerose

Publications (2)

Publication Number Publication Date
CA2312021A1 CA2312021A1 (fr) 1999-05-27
CA2312021C true CA2312021C (fr) 2008-08-26

Family

ID=9513423

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002312021A Expired - Fee Related CA2312021C (fr) 1997-11-17 1998-11-16 Utilisation des ketolides pour prevenir les complications thrombotiques arterielles liees a l'atherosclerose

Country Status (35)

Country Link
US (1) US20080139489A1 (cg-RX-API-DMAC7.html)
EP (1) EP1030673B1 (cg-RX-API-DMAC7.html)
JP (1) JP4550273B2 (cg-RX-API-DMAC7.html)
KR (1) KR20010032130A (cg-RX-API-DMAC7.html)
CN (1) CN1286633A (cg-RX-API-DMAC7.html)
AP (1) AP1196A (cg-RX-API-DMAC7.html)
AR (1) AR014119A1 (cg-RX-API-DMAC7.html)
AT (1) ATE271875T1 (cg-RX-API-DMAC7.html)
AU (1) AU744419B2 (cg-RX-API-DMAC7.html)
BG (1) BG104427A (cg-RX-API-DMAC7.html)
BR (1) BR9814199A (cg-RX-API-DMAC7.html)
CA (1) CA2312021C (cg-RX-API-DMAC7.html)
DE (1) DE69825308T2 (cg-RX-API-DMAC7.html)
DZ (1) DZ2654A1 (cg-RX-API-DMAC7.html)
EA (1) EA003322B1 (cg-RX-API-DMAC7.html)
EE (1) EE04095B1 (cg-RX-API-DMAC7.html)
ES (1) ES2224446T3 (cg-RX-API-DMAC7.html)
FR (1) FR2771008B1 (cg-RX-API-DMAC7.html)
GE (1) GEP20032968B (cg-RX-API-DMAC7.html)
HR (1) HRP20000314A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0004507A3 (cg-RX-API-DMAC7.html)
ID (1) ID24940A (cg-RX-API-DMAC7.html)
IL (1) IL136149A0 (cg-RX-API-DMAC7.html)
MA (1) MA26566A1 (cg-RX-API-DMAC7.html)
NO (1) NO20002435L (cg-RX-API-DMAC7.html)
NZ (1) NZ504305A (cg-RX-API-DMAC7.html)
OA (1) OA11411A (cg-RX-API-DMAC7.html)
PL (1) PL340373A1 (cg-RX-API-DMAC7.html)
SK (1) SK7042000A3 (cg-RX-API-DMAC7.html)
TN (1) TNSN98206A1 (cg-RX-API-DMAC7.html)
TR (1) TR200001384T2 (cg-RX-API-DMAC7.html)
TW (1) TW472061B (cg-RX-API-DMAC7.html)
WO (1) WO1999025365A1 (cg-RX-API-DMAC7.html)
YU (1) YU29600A (cg-RX-API-DMAC7.html)
ZA (1) ZA9810357B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777282B1 (fr) * 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
ATE344269T1 (de) * 1998-12-10 2006-11-15 Pfizer Prod Inc Carbamat und carbazat ketolid antibiotika
DK1147121T3 (da) * 1999-01-27 2004-04-13 Pfizer Prod Inc Ketolidantibiotika
EP1114826A3 (en) * 1999-12-29 2001-10-31 Pfizer Products Inc. Novel antibacterial and prokinetic macrolides
HUP0300370A3 (en) 2000-04-04 2005-07-28 Smithkline Beecham Plc 2-hydroxy-mutilin carbamate derivatives of antibacterial effect process for preparation and pharmaceutical compositions containing them
JP2004323414A (ja) * 2003-04-24 2004-11-18 Japan Science & Technology Agency 14員環マクロライド化合物を利用した、血管平滑筋の増殖に起因する疾患治療剤
GB0402578D0 (en) * 2004-02-05 2004-03-10 Cambridge Theranostics Ltd Methods of treatment of atherosclerosis
KR20130120458A (ko) * 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2249892A (en) * 1991-06-14 1993-01-12 Board Of Regents Of The University Of Washington, The Diagnosis and treatment of arterial chlamydial granuloma
FR2718450B1 (fr) * 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) * 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2742757B1 (fr) * 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US6271255B1 (en) * 1996-07-05 2001-08-07 Biotica Technology Limited Erythromycins and process for their preparation
GB9621771D0 (en) * 1996-10-18 1996-12-11 St George S Enterprises Ltd Method of treatment of heart disease
FR2757168B1 (fr) * 1996-12-12 1999-06-11 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
EP0895999A1 (en) * 1997-08-06 1999-02-10 Pfizer Products Inc. C-4" substituted macrolide antibiotics

Also Published As

Publication number Publication date
NO20002435D0 (no) 2000-05-11
YU29600A (sh) 2003-02-28
NO20002435L (no) 2000-07-07
JP4550273B2 (ja) 2010-09-22
WO1999025365A1 (fr) 1999-05-27
BG104427A (en) 2001-02-28
CA2312021A1 (fr) 1999-05-27
BR9814199A (pt) 2000-09-26
EP1030673A1 (fr) 2000-08-30
DE69825308D1 (de) 2004-09-02
EE200000244A (et) 2001-06-15
DE69825308T2 (de) 2005-08-04
AU744419B2 (en) 2002-02-21
DZ2654A1 (fr) 2003-03-22
SK7042000A3 (en) 2000-12-11
JP2001523644A (ja) 2001-11-27
TNSN98206A1 (fr) 2005-03-15
AU1242599A (en) 1999-06-07
HUP0004507A3 (en) 2001-12-28
CN1286633A (zh) 2001-03-07
AP2000001825A0 (en) 2000-06-30
ES2224446T3 (es) 2005-03-01
GEP20032968B (en) 2003-05-27
KR20010032130A (ko) 2001-04-16
AR014119A1 (es) 2001-02-07
EA003322B1 (ru) 2003-04-24
TW472061B (en) 2002-01-11
ZA9810357B (en) 1999-11-12
TR200001384T2 (tr) 2001-06-21
EP1030673B1 (fr) 2004-07-28
PL340373A1 (en) 2001-01-29
HRP20000314A2 (en) 2001-02-28
US20080139489A1 (en) 2008-06-12
EE04095B1 (et) 2003-08-15
HUP0004507A1 (hu) 2001-05-28
AP1196A (en) 2003-08-18
EA200000531A1 (ru) 2000-10-30
NZ504305A (en) 2002-11-26
FR2771008B1 (fr) 2000-04-28
ATE271875T1 (de) 2004-08-15
IL136149A0 (en) 2001-05-20
ID24940A (id) 2000-08-31
MA26566A1 (fr) 2004-12-20
OA11411A (fr) 2004-04-20
FR2771008A1 (fr) 1999-05-21

Similar Documents

Publication Publication Date Title
KR100879559B1 (ko) 미토콘드리아 장애의 치료 또는 예방용 제약조성물
JPS62158210A (ja) L−ド−パの直腸吸収形態
WO1982001821A1 (en) Antimycotic synergistic pharmaceutical compositions and process for the preparation thereof
EP3512865B1 (fr) Esters des derivés 3-polyaminés des acides biliaires pour le traitement des infections
US20080139489A1 (en) Use of ketolides for preventing arterial thrombotic complications related to atherosclerosis
EP0974598B1 (fr) Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments
HU228026B1 (en) Compositions comprising an hiv protease inhibitor and a water soluble vitamin e compound
US4002741A (en) Meglumine complex fungicidal polyene macrolide antibiotic compositions and treatment method
EP3512864B1 (fr) Dérivés amides de squalamine pour le traitement des infections
CA2118564C (fr) Derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
KR0133555B1 (ko) 5-플루오로우라실계 화합물에 기인한 염증의 발생을 억제할 수 있는 비-주사제 형태의 항암조성물
LU83928A1 (fr) Acides amino-2 halogenobenzoyl-3 methyphenylacetiques et leurs esters et sels utiles comme medicaments anti-inflammatoires et analgesiques
NL8101987A (nl) De verbinding 4-amino-1-beta-d-ribofuranosyl-1h-imidazo/4.5-c/-pyridine of een farmaceutisch aanvaardbaar zuuradditiezout daarvan; farmaceutisch preparaat.
WO1998025942A1 (fr) Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
HUP0203790A2 (hu) (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére
JP2002540150A (ja) ウイルス治療
US3852454A (en) Treatment of rheumatoid arthritis
CA1270762A (fr) Compositions pharmaceutiques renfermant un derive de l'acide maleopimarique
US4007166A (en) Meglumine complexes of fungicidal polyene macrolide antibiotics and method of preparing same
HU207216B (en) Process for producing absorption-improving systhems and pharmaceutical compositions containing them
JP2889491B2 (ja) 血圧降下剤
LU84427A1 (fr) A titre de medicaments,certains derives mono substitues de l'acide 4-phenyl 4-oxo buten-2-oique,ainsi que les compositions les renfermant
EP1098901B1 (fr) Nouveaux derives de la 6-deoxy erythromycine, leur procede de preparation et leur application comme medicaments
KR20010006136A (ko) 궤양성 대장염 및/또는 크론병 예방 및 치료제
JPH0788304B2 (ja) 高アンモニア血症治療剤

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151116